³»ºÐºñ °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : °Ë»ç À¯Çüº°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)
Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (FSH, Insulin), By Technology (Tandem Mass Spectrometry, Immunoassay), By End-use, By Region, And Segment Forecasts, 2023 - 2030
»óǰÄÚµå
:
1363022
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2023³â 09¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 180 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ³»ºÐºñ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 214¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ¿¹Ãø ±â°£ µ¿¾È 8.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼ºÀλӸ¸ ¾Æ´Ï¶ó ³ë³âÃþ¿¡¼ ºñ¸¸, ´ç´¢º´, °©»ó¼±°ú °°Àº »ýȰ½À°üº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ³»ºÐºñ °Ë»ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °³ÀÎÀÇ Á¤±âÀûÀÎ ³»ºÐºñ °Ë»ç´Â Àü¹ÝÀûÀÎ °Ç° À¯Áö¿¡ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼¼°è ³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.
WHO Åë°è¿¡ µû¸£¸é 2020³â 5¼¼ ¹Ì¸¸ ¾î¸°ÀÌ Áß 3,900¸¸ ¸í ÀÌ»óÀÌ °úüÁß ¶Ç´Â ºñ¸¸ÀÎ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÁÂ½Ä »ýȰ°ú °Ç°¿¡ ÇØ·Î¿î ½Ä½À°üÀº ÀÏ¹Ý Àα¸ÀÇ ºñ¸¸°ú ´ç´¢º´ÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ß»ýÀº ´ë»ç ±â´É ¹× °ü·Ã È£¸£¸ó Àå¾Ö¿¡ ´ëÇÑ ¸¹Àº ¿¬±¸¸¦ Ã˹߽ÃÄ×½À´Ï´Ù.
Á¤ºÎ¿Í ¹Î°£´ÜüÀÇ ÀÚ±Ý Áö¿øµµ °úÇа踦 ¿òÁ÷À̰í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, NIHÀÇ NIDDK(National Institute of Diabetes, Digestive and Kidney Diseases)´Â Áúº´¿¡ ´ëÇÑ ´õ ³ªÀº ÀÌÇØ¸¦ ÅëÇÑ °Ç° ÁõÁøÀ» ¸ñÇ¥·Î ¸¹Àº ÈÄ¿ø ¿¬±¸ ÇÁ·Î±×·¥À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ÁߺΠ½ÉÆ÷Áö¾öÀÔ´Ï´Ù. À̸¦ ÅëÇØ °úÇÐÀû Áö½ÄÀÇ ±³È¯°ú ±³·ù¸¦ °¡´ÉÇÏ°Ô Çϰí, Áö¿ª Â÷¿øÀÇ Çù·ÂÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ÀÎüÀÇ ³»ºÐºñ ±â´É¿¡ ´ëÇÑ ÀÌÇØ¸¦ ÃËÁøÇÏ°í ³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Àú°³¹ß±¹ ¹× ½ÅÈï±¹¿¡¼ÀÇ ÀÎ½Ä ºÎÁ·Àº ³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» µÐȽÃų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ȯ°æ°ú »óȯ ¸ðµ¨ÀÇ ºÎÀç·Î ÀÎÇØ ÀÌ Áö¿ªÀÇ °³ÀεéÀÌ Á¤±âÀûÀÎ ³»ºÐºñ °Ë»ç¸¦ ¹Þ´Â °ÍÀ» ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª COVID-19 ÆÒµ¥¹Í ±â°£ µ¿¾È °Ç°ÇÑ ½Ã½ºÅÛ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÌµé ±¹°¡¿¡¼µµ °Ë»ç ºóµµ°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COVID-19 Àü¿°º´Àº ³»ºÐºñ °Ë»ç ÀÀ¿ë¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖÀ¸¸ç, COVID-19 °¨¿°Àº ¸¹Àº Àå±â¿¡ ¼Õ»óÀ» ÀÔÈ÷´Â Àü½Å ÁúȯÀ» À¯¹ßÇÕ´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ È¯ÀÚµéÀº ¸¹Àº ´ë»ç Àå¾Ö¿Í È£¸£¸ó Àå¾Ö¸¦ °¡Áö°í ÀÖ¾î ³»ºÐºñ ¿¬±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ³»ºÐºñÇÐȸ ȸ¿øµéÀº COVID-19°¡ ³»ºÐºñ°è¿¡ ¹ÌÄ¡´Â ´Ü±â ¹× Àå±âÀûÀÎ ¿µÇâÀ» ÆÄ¾ÇÇϰí ÀÌÇØÇϱâ À§ÇØ COVID-19 ¿¬±¸¸¦ Áö¿øÇϱâ À§ÇØ 100¾ï ´Þ·¯¸¦ ½ÂÀÎÇß½À´Ï´Ù. ¸¶Âù°¡Áö·Î 2020³â 9¿ù ¹Ì±¹ ´ç´¢º´ Çùȸ´Â ´ç´¢º´°ú COVID-19ÀÇ ¿¬°ü¼ºÀ» Á¶»çÇϱâ À§ÇØ ´Ù¾çÇÑ ¿¬±¸ ÇÁ·ÎÁ§Æ®¿¡ 100¸¸ ´Þ·¯¸¦ ÅõÀÚÇß½À´Ï´Ù. µû¶ó¼ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
¶ÇÇÑ, °¨±ÝÀ¸·Î ÀÎÇÑ À̵¿ Á¦ÇѰú Á¦¾àÀ¸·Î ÀÎÇØ ÀÇ·á »ó´ã ¹× ÀçÅà °Ëü äÃë ¼ºñ½º¸¦ À§ÇÑ µðÁöÅÐ Ç÷§ÆûÀÌ È°¼ºÈµÇ°í ÀÖ½À´Ï´Ù. Áý¿¡¼ È£¸£¸ó ¼öÄ¡¸¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ÇöÀå Áø·á ±â±â ¹× ŰƮÀÇ °¡¿ë¼ºµµ Àüü ³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ±â¾÷µéÀº ¶ÇÇÑ ³»ºÐºñ °Ë»ç ½ÃÀåÀ» ¼ºÀå½Ãų °ÍÀ¸·Î ¿¹»óµÇ´Â ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Áö¿ªÀû ÀÔÁö¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. Çù¾÷, ÆÄÆ®³Ê½Ê, ¼¼°è ÁøÃâÀº ¼öÀÍ Ã¢ÃâÀ» ÃËÁøÇϱâ À§ÇÑ ÁÖ¿ä ¾÷üµéÀÇ »ç¾÷ Àü·«ÀÇ ÀϺÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù Laboratory Corporation of America Holdings(Labcorp)´Â ¹Ì±¹ Àεð¾Ö³ª ÁÖ¿¡ »õ·Î¿î ½ÇÇè½ÇÀ» °³¼³ÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Àεð¾Ö³ªÁÖ »ç¿ì½ºº¥µå(South Bend)ÀÇ »õ·Î¿î Áø´Ü »ç¾÷Àº ÀÌ Áö¿ªÀÇ È¯ÀÚ»Ó¸¸ ¾Æ´Ï¶ó ÀÇ»çµéµµ ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï ȸ»çÀÇ ¼ºñ½º¸¦ °ÈÇÒ °ÍÀÔ´Ï´Ù.
³»ºÐºñ °Ë»ç ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- °Ë»ç À¯Çüº°·Î´Â Àΰ£ À¶¸ð¼º ¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) È£¸£¸ó °Ë»ç°¡ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Á¤·®Àû Æò°¡¸¦ À§ÇÑ ½ÇÇè½Ç ¹× º´¿ø °Ë»ç¿Í ÇÔ²² ¾à±¹¿¡¼ÀÇ ÀÚ°¡ Å×½ºÆ® ŰƮÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ÀӽŠÁÖ¼öº° °Ë»ç ºóµµ ¹× °¡Àӱ⠿©¼º Àα¸ÀÇ Áõ°¡µµ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇß½À´Ï´Ù.
- ±â¼úº°·Î´Â ¸é¿ª ºÐ¼®ÀÌ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ´Â ¸é¿ª ºÐ¼®¿¡ ±â¹ÝÇÑ °ËÃâ ±â¼úÀ» »ç¿ëÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ±â±â°¡ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù. ¸é¿ª ºÐ¼® ±â¼ú¿¡ ÀÇÁ¸ÇÏ´Â ¸¹Àº ±â±â ¹× °Ë»ç ÆÐ³ÎÀÌ ³»ºÐºñ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â »ó¾÷¿ë °Ë»ç½ÇÀÌ 2022³â ¸ÅÃâ¿¡ Å©°Ô ±â¿©Çß½À´Ï´Ù. ³»ºÐºñÇÐ ¹× »ý½Ä ±â´ÉÀ» À§ÇÑ ´Ù¾çÇÑ °Ë»ç ÆÐ³ÎÀÇ ½ÇÇö °¡´É¼º°ú °¡¿ë¼º, °¡Á¤ ³» äÃë¿Í °°Àº ¼ºñ½º ¹× µðÁöÅÐ Ç÷§ÆûÀÇ Á¸Àç°¡ ºÎ¹® Á¡À¯À²À» È®´ëÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
- 2022³â ³»ºÐºñ °Ë»ç ½ÃÀå ¸ÅÃâÀº ºÏ¹Ì°¡ °¡Àå ³ô¾Ò½À´Ï´Ù. ÀÌ´Â ¹Ì±¹ Àα¸¿¡ °©»ó¼± Áúȯ, ´ç´¢º´ ¹× ºñ¸¸ÀÌ ¸¹ÀÌ Á¸ÀçÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ ÀÇ·á ¹ßÀü°ú ÁöÃâ ÆÐÅÏÀÇ Áõ°¡µµ ¸ÅÃâ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ³»ºÐºñ °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ³»ºÐºñ °Ë»ç ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ³»ºÐºñ °Ë»ç : °Ë»ç À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®
- ³»ºÐºñ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ³»ºÐºñ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ¿¡½ºÆ®¶óµð¿Ã(E2) °Ë»ç
- ³Æ÷ÀÚ±ØÈ£¸£¸ó(FSH) °Ë»ç
- »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó(hCG) È£¸£¸ó °Ë»ç
- Ȳü Çü¼º È£¸£¸ó(LH) °Ë»ç
- µ¥È÷µå·Î¿¡ÇǾȵå·Î½ºÅ׷РȲ»ê¿°(DHEAS) °Ë»ç
- ÇÁ·Î°Ô½ºÅ×·Ð °Ë»ç
- Å×½ºÅ佺Å×·Ð °Ë»ç
- °©»ó¼± ÀÚ±Ø È£¸£¸ó(TSH) °Ë»ç
- ÇÁ·Î¶ôƾ °Ë»ç
- ÄÚ¸£Æ¼¼Ö °Ë»ç
- Àν¶¸° °Ë»ç
- ±âŸ
Á¦5Àå ³»ºÐºñ °Ë»ç : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®
- ³»ºÐºñ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ³»ºÐºñ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ÅÙ´ý Áú·®ºÐ¼®¹ý
- ¸é¿ªÃøÁ¤
- ´ÜŬ·Ð ¹× ´ÙŬ·Ð Ç×ü ±â¼ú
- ¼¾¼ ±â¼ú
- ÀÓ»óÈÇÐ
- ±âŸ
Á¦6Àå ³»ºÐºñ °Ë»ç : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ³»ºÐºñ °Ë»ç ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ³»ºÐºñ °Ë»ç ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- º´¿ø
- »ó¾÷ °Ë»ç½Ç
- ¿Ü·¡ Áø·á ¼¾ÅÍ
- ±âŸ
Á¦7Àå ³»ºÐºñ °Ë»ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª Àü¸Á
- Áö¿ªº° ³»ºÐºñ °Ë»ç ½ÃÀå : ¸¶ÄÏÇ÷¹À̽ºÀÇ Áß¿äÇÑ Æ÷ÀÎÆ®
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- Abbott Laboratories
- AB Sciex
- Agilent Technologies Inc.
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd.
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Ortho Clinical Diagnostics
ksm
¿µ¹® ¸ñÂ÷
Endocrine Testing Market Growth & Trends:
The global endocrine testing market size is expected to reach USD 21.42 billion by 2030, registering a CAGR of 8.4% during the forecast period, according to a new report by Grand View Research, Inc.. The growing prevalence of life style diseases such as obesity coupled with diabetes & thyroid among the adult as well as the geriatric population is driving the need for endocrine testing. The routine endocrine testing in individuals will help in overall maintenance of health and thus this awareness of better health is significantly contributing to the global endocrine testing market growth.
As per the statistics by WHO, more than 39 million children in 2020 who were under the age of 5 were overweight or obese. The sedentary life along with unhealthy diet choices have contributed to obesity as well as diabetes in the general population. This occurrence of diseased conditions has also prompted many researches into the metabolic functions and related hormonal disorders.
Funding from government and private organizations has also driven the scientific community. For instance, the NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) by NIH drives many sponsored research programs towards improving health by better understanding of diseases. One such effort by NIDDK was the mid-atlantic symposium conducted in September 2022 for diabetes and obesity research. This will enable scientific knowledge exchange and interactions and allow collaboration at the regional level. Such initiatives will drive the understanding of endocrine function in the human body and will further enable the endocrine testing market growth.
The lack of awareness in underdeveloped and developing countries is anticipated to slow the growth of endocrine testing market. The developing health care settings and absence of reimbursement models restrain the individuals in these regions to undergo routine endocrine testing. However, with the growing consciousness of a healthy system during the COVID-19 pandemic is expected to upswing the testing frequency for these countries as well.
The outbreak of COVID-19 has created lucrative opportunities for the application of endocrine testing. COVID-19 infections cause a systemic disease that injures many organs. Therefore, these patients have many metabolic and hormonal disturbances that led to an increase in the number of endocrine research. For instance, in March 2021, Endocrine society members sanctioned USD 10 billion to support COVID-19 research to identify and understand the short and long-term COVID-19 effects on the endocrine system. Similarly, in September 2020, The American Diabetes Association invested USD 1 million to fund various research projects for investigating the link between diabetes and COVID-19. Thus, it will increase the demand and further boost market growth.
In addition, the limitation of movement and restrictions due to the lockdown encouraged the digital platform for medical consultation and at home sample collection services as well. The availability of point-of-care devices and kits for the detection of hormone levels at home is also driving the overall growth of endocrine testing market.
The market players are also expanding their regional presence due to various factors that are anticipated to grow the endocrine testing market. Collaboration, partnerships and global expansions are some of the business strategies by the key players to drive revenue generation. For instance, in February 2022 Laboratory Corporation of America Holdings (Labcorp) announced opening of a new laboratory in Indiana, U.S. The new diagnostics business in South Bend, Indiana will enhance the company's services and make their offerings accessible to both patients as well as physicians in this region.
Endocrine Testing Market Report Highlights:
- By test type, the human Chorionic Gonadotropin (hCG) hormone testing accounted for the largest share in 2022, driven by the presence of self-test kits at pharmacy stores, along with tests in laboratories or hospitals for quantitative evaluation. Moreover, the frequency of testing during different weeks of pregnancy and high number of fertile female population are also the contributing factors.
- By technology, immunoassay dominated the 2022 market, owing to the presence of instruments by key players which uses immunoassay-based detection techniques. The large number of instruments and test panels which rely on immunoassay technology, drives the endocrine testing market growth.
- By end-user, commercial laboratories contributed majorly to the revenue generation in 2022. The feasibility & availability of variety of testing panels for endocrinology and reproductive functions, services like at home collection and presence of digital platforms led to the increased segment share.
- North America had the highest revenue generated in 2022 for endocrine testing market. This is attributed to the vast presence of thyroid disorders, diabetes and obesity within the US population. Additionally, developed healthcare and increased spending pattern in this region also led to higher revenue generation.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Test Type
- 1.1.2. Technology
- 1.1.3. End-use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Test Type outlook
- 2.2.2. Technology outlook
- 2.2.3. End-use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Endocrine Testing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Endocrine Testing Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Endocrine Testing: Test Type Estimates & Trend Analysis
- 4.1. Endocrine Testing Market: Key Takeaways
- 4.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Estradiol (E2) Test
- 4.3.1. Estradiol (E2) test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Follicle Stimulating Hormone (FSH) Test
- 4.4.1. Follicle Stimulating Hormone (FSH) test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Human Chorionic Gonadotropin (hCG) Hormone Test
- 4.5.1. Human Chorionic Gonadotropin (hCG) hormone test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Luteinizing Hormone (LH) Test
- 4.6.1. Luteinizing Hormone (LH) test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.7. Dehydroepiandrosterone Sulfate (DHEAS) Test
- 4.7.1. Dehydroepiandrosterone Sulfate (DHEAS) test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.8. Progesterone Test
- 4.8.1. Progesterone test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.9. Testosterone Test
- 4.9.1. Testosterone test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.10. Thyroid Stimulating Hormone (TSH) Test
- 4.10.1. Thyroid Stimulating Hormone (TSH) test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.11. Prolactin Test
- 4.11.1. Prolactin test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.12. Cortisol Test
- 4.12.1. Cortisol test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.13. Insulin Test
- 4.13.1. Insulin test market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.14. Others
- 4.14.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Endocrine Testing: Technology Estimates & Trend Analysis
- 5.1. Endocrine Testing Market: Key Takeaways
- 5.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Tandem Mass Spectrometry
- 5.3.1. Tandem mass spectrometry market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Immunoassay
- 5.4.1. Immunoassay market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Monoclonal & Polyclonal Antibody Technologies
- 5.5.1. Monoclonal & polyclonal antibody technologies market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Sensor Technology
- 5.6.1. Sensor technology market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.7. Clinical Chemistry
- 5.7.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Endocrine Testing: End-use Estimates & Trend Analysis
- 6.1. Endocrine Testing Market: Key Takeaways
- 6.2. Endocrine Testing Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Hospitals
- 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Commercial Laboratories
- 6.4.1. Commercial laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Ambulatory Care Centers
- 6.5.1. Ambulatory care centers market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Endocrine Testing Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Endocrine Testing Market by Region: Key Marketplace Takeaway
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Sweden
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Norway
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Denmark
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. Saudi Arabia
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Abbott Laboratories
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. AB Sciex
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Agilent Technologies Inc.
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. bioMerieux SA
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Bio-Rad Laboratories Inc.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. DiaSorin S.p.A.
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. F. Hoffmann-La Roche Ltd.
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. Laboratory Corporation of America Holdings
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Quest Diagnostics Incorporated
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Ortho Clinical Diagnostics
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
°ü·ÃÀÚ·á